The pharmaceutical manufacturing market is projected to register a CAGR of 9.38% during 2027–2032, with Asia-Pacific emerging as the fastest-growing regional market.

Hyderabad, India, Nov. 09, 2026 (GLOBE NEWSWIRE) -- The Pharmaceutical Manufacturing Market is projected to grow from USD 549.2 billion in 2026 to USD 603.7 billion in 2027, reaching USD 945.2 billion by 2032, at a CAGR of 9.38% during the forecast period (2027–2032). Increasing pharmaceutical research and development investments, rising demand for biologics and biosimilars, and the expansion of contract manufacturing capabilities are supporting market growth. Manufacturers are also investing in automation, continuous production technologies, and regional manufacturing capacity to improve operational efficiency and strengthen supply-chain resilience. 

The industry is undergoing a shift toward more specialized and technology-driven production. Growing demand for complex therapies, including oncology medicines and biologics, is increasing the need for advanced manufacturing infrastructure and specialized quality-control systems. At the same time, pharmaceutical companies are relying more heavily on contract development and manufacturing organizations (CDMOs) to access production expertise and flexible capacity. However, pricing pressure, regulatory requirements, and dependence on internationally sourced manufacturing inputs continue to influence investment decisions. 

Pharmaceutical Manufacturing Market Share by Region 

North America accounted for the largest regional share of the pharmaceutical manufacturing market, representing 36.41% in 2026. Its established pharmaceutical industry, significant research and development expenditure, advanced production infrastructure, and presence of major drug manufacturers support its leading position. 

Asia-Pacific is projected to be the fastest-growing region during 2027–2032. Expanding pharmaceutical production capabilities, investments in domestic active pharmaceutical ingredient manufacturing, and rising demand for medicines across major economies are supporting regional growth. Government initiatives encouraging local production and supply-chain diversification are also strengthening the region's manufacturing outlook. 

“Pharmaceutical manufacturing is increasingly shaped by the need to balance production scale with flexibility, quality, and supply reliability. As biologics, biosimilars, and specialized therapies gain importance, manufacturers are investing in advanced capabilities and external partnerships to support evolving production requirements,” says Soumya Goud, Senior Research Manager at Mordor Intelligence. 

Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights: https://www.mordorintelligence.com/ja/industry-reports/pharmaceutical-manufacturing?utm_source=globenewswire 

Pharmaceutical Manufacturing Market Trends & Forecast 

Increasing R&D Investment Strengthens Commercial Production Requirements 

Rising pharmaceutical research and development expenditure is creating opportunities for manufacturers as new drug candidates progress toward commercialization. The development of complex therapies requires specialized production processes, validated facilities, and consistent quality systems. As pharmaceutical companies advance their pipelines, manufacturing readiness is becoming an important consideration earlier in the development process. This is encouraging investment in process development, production infrastructure, and specialized manufacturing capabilities. 

Automation and Continuous Processing Reshape Production Efficiency 

Pharmaceutical manufacturers are increasingly evaluating automation and continuous manufacturing technologies to improve production consistency and operational efficiency. Digital monitoring, AI-enabled automation, and advanced process controls can help manufacturers identify deviations, improve quality oversight, and optimize existing production lines. Continuous manufacturing is also gaining attention as companies seek to reduce production interruptions and improve capacity utilization. These investments are supporting the gradual modernization of conventional manufacturing facilities. 

Biosimilar Expansion and Localized API Production Influence Capacity Planning 

Growing biosimilar development and the entry of competing products following patent expirations are increasing demand for scalable manufacturing capabilities. Producers must establish reliable production processes that meet regulatory requirements while supporting competitive pricing. In parallel, governments and pharmaceutical companies are encouraging the localization of active pharmaceutical ingredient production to reduce dependence on concentrated international supply chains. These developments are influencing facility investments, sourcing strategies, and partnerships across the pharmaceutical manufacturing industry. 

Pharmaceutical Manufacturing Market Segmentation Overview 

The pharmaceutical manufacturing market is segmented by molecule type, manufacturing mode, formulation, manufacturing technology, application, prescription type, and geography. 

  • By Molecule Type 
  • Conventional Drugs 
  • Biologics and Biosimilars 
  • By Manufacturing Mode 
  • In-house Manufacturing 
  • Contract Manufacturing Organization (CMO) / Contract Development and Manufacturing Organization (CDMO) 
  • By Formulation 
  • Tablets 
  • Capsules 
  • Injectables 
  • Topical and Transdermal 
  • Nasal and Pulmonary Sprays 
  • Others 
  • By Manufacturing Technology 
  • Batch Manufacturing 
  • Continuous Manufacturing 
  • Single-Use Manufacturing 
  • By Application 
  • Oncology 
  • Diabetes 
  • Cardiovascular 
  • Neurology 
  • Respiratory 
  • Others 
  • By Prescription Type 
  • Prescription Medicines 
  • Over-the-Counter (OTC) Medicines 
  • By Geography 
  • North America 
  • Europe 
  • Asia-Pacific 
  • Middle East and Africa 
  • South America 

Pharmaceutical Manufacturing Market Competitive Outlook 

The pharmaceutical manufacturing market has a moderately concentrated competitive structure, with established multinational pharmaceutical companies maintaining significant production capabilities and global distribution networks. Competition is influenced by manufacturing scale, product portfolios, regulatory compliance, technological investments, and the ability to maintain consistent product quality. 

Companies are strengthening their positions through production capacity expansion, investments in biologics and specialized medicines, and partnerships with external manufacturing providers. The growing importance of contract manufacturing is also creating opportunities for organizations that can offer flexible production capabilities and support complex pharmaceutical formulations. Meanwhile, supply-chain diversification and regional manufacturing investments are influencing long-term competitive strategies. 

Pharmaceutical Manufacturing Industry Leaders 

  • Pfizer Inc. 
  • AstraZeneca plc 
  • Sanofi SA 
  • F. Hoffmann-La Roche AG 
  • Eli Lilly and Company 

Explore Trending Reports from Mordor Intelligence 

Moist Wound Dressings Market Size 

The Moist Wound Dressings Market is expected to grow from USD 5.31 billion in 2026 to USD 6.86 billion by 2031, registering a CAGR of 5.24%, supported by the rising prevalence of chronic wounds, increasing surgical procedures, and growing demand for advanced wound care products.  

Hemostasis Valve Market Share 

The Hemostasis Valve Market is projected to expand from USD 203.9 million in 2026 to USD 263.18 million by 2031, at a CAGR of 5.24%, driven by increasing minimally invasive procedures, rising demand for vascular access devices, and advancements in interventional medical technologies.  

Tablet Hardness Testers Market Analysis 

The Tablet Hardness Testers Market is expected to grow from USD 345.72 million in 2025 to USD 446.90 million by 2030, registering a CAGR of 5.27%, supported by expanding pharmaceutical manufacturing, stringent quality control requirements, and increasing adoption of automated testing equipment. 

Filter Integrity Test Market Trends 

The Filter Integrity Test Market is projected to increase from USD 88.79 million in 2026 to USD 114.29 million by 2031, at a CAGR of 5.16%, driven by growing biopharmaceutical production, stringent regulatory standards, and the need to ensure filtration efficiency and product sterility.  

Counterfeit Drug Detection Device Market Growth 

The Counterfeit Drug Detection Device Market is expected to expand from USD 1.63 billion in 2026 to USD 2.21 billion by 2031, registering a CAGR of 6.30%, supported by rising concerns over counterfeit medicines, stricter pharmaceutical supply chain regulations, and increasing adoption of authentication and verification technologies. 

About Mordor Intelligence 

Mordor Intelligence is a global market intelligence firm, founded in 2014, helping businesses make informed decisions through data-driven insights, industry expertise, and advanced analytics. With 550+ domain experts and on-ground specialists across 180+ countries, the company delivers comprehensive intelligence across aerospace & defense, agriculture, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, and logistics. 

Its offerings include syndicated industry reports, custom research and advisory, and subscription platforms such as Synapse, Data Center Intelligence, and Robotics Intelligence. Mordor Intelligence is ISO 9001:2015 and ISO/IEC 27001:2022 certified, a member of ESOMAR and the Market Research Society of India, and a four-time Great Place to Work® honoree. Learn more at mordorintelligence.com. 


CONTACT: For any inquiries or to access the full report, please contact:  

media@mordorintelligence.com  

https://www.mordorintelligence.com